Characterization of autoantibodies against components of the nuclear pore complexes: High frequency of anti-p62 nucleoporin antibodies

Annals of the New York Academy of Sciences

Volumn 1109, Issue , 2007, Pages 519-530

  Wȩsierska Ga̧dek, Józefa ^a   Klima, Anna ^a   Komina, Oxana ^a   Ranftler, Carmen ^a   Invernizzi, Pietro ^b   Penner, Edward ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF MILAN   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

AMAs; ANAs; Gp210 glycoprotein; Nuclear envelope; Prognostic value; Severity of disease

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; NUCLEOPORIN; PROTEIN P62; RECOMBINANT PROTEIN; WHEAT GERM AGGLUTININ; ANTINUCLEAR ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; NONHUMAN; NUCLEAR PORE COMPLEX; PRIMARY BILIARY CIRRHOSIS; PROGNOSIS; PROTEIN PURIFICATION; RAT; STATISTICAL SIGNIFICANCE; ARTICLE; BILIARY CIRRHOSIS; BLOOD; HUMAN; IMMUNOLOGY; MOLECULAR WEIGHT; NUCLEAR PORE;

ANAS; TRITICUM AESTIVUM;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; HUMANS; LIVER CIRRHOSIS, BILIARY; MOLECULAR WEIGHT; NUCLEAR PORE; NUCLEAR PORE COMPLEX PROTEINS;

EID: 34848847520     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1398.058     Document Type: Conference Paper

References (38)

1. TALWALKAR, J.A. & K.D. LINDOR. 2003. Primary biliary cirrhosis. Lancet 362: 53-61.
2. CHRISTENSEN, E., J. CROWE, D. DONIACH, et al. 1980. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78: 236-246.
3. INVERNIZZI, P., C. SELMI, C. RANFTLER, et al. 2005. Antinuclear antibodies in primary biliary cirrhosis. Semin. Liver Dis. 25: 298-310.
4. LOZANO, F., A. PARES, L. BORCHE, et al. 1988. Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis. Hepatology 8: 930-938.
5. LASSOUED, K., R. BRENARD, F. DEGOS, et al. 1990. Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis. A clinical and immunological study of a series of 150 patients with primary biliary cirrhosis. Gastroenterology 99: 181-186.
6. COURVALIN, J.C., K. LASSOUED, E. BARTNIK, et al. 1990. The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J. Clin. Invest. 86: 279-285.
7. NICKOWITZ, R.E., R.W. WOZNIAK, F. SCHAFFNER, et al. 1994. Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis. Gastroenterology 106: 193-199.
8. WESIERSKA-GADEK, J., H. HOHENAUER, E. HITCHMAN, et al. 1995a. Autoantibodies from patients with primary biliary cirrhosis preferentially react with the aminoterminal domain of nuclear pore complex glycoprotein gp210. J. Exp. Med. 182: 1159-1162.
9. WESIERSKA-GADEK, J., H. HOHENAUER, E. HITCHMAN, et al. 1996. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 110: 840-847.
10. WESIERSKA-GADEK, J., H. HOHENAUER, E. HITCHMAN, et al. 1995b. Autoantibodies against constituents of nuclear pore complexes in patients with primary biliary cirrhosis and autoimmune hepatitis. Acta Biochim. Pol. 42: 197-200.
11. MIYACHI, K., M. SHIBATA, Y. ONOZUKA, et al. 1996. Primary biliary cirrhosis sera recognize not only gp210 but also proteins of the p62 complex bearing N-acetylglucosamine residues from rat liver nuclear envelope. Anti-p62 complex antibody in PBC. Mol. Biol. Rep. 23: 227-234.
12. DAVIS, L.I. & G. BLOBEL. 1987. Nuclear pore complex contains a family of glycoproteins that includes p62: glycosylation through a previously unidentified cellular pathway. Proc. Natl. Acad. Sci. USA 84: 7552-7556.
13. D'ONOFRIO, M., C.M. STARR, M.K. PARK, et al. 1988. Partial cDNA sequence encoding a nuclear pore protein modified by O-linked N-acetylglucosamine. Proc. Natl. Acad. Sci. USA 85: 9595-9599.
14. WESIERSKA-GADEK, J., C. RANFTLER, E. HITCHMAN, et al. 2005. Reactivity of human sera from patients suffering from PBC with human recombinant p62 nucleoporin. [abstract]. Cell. Mol. Biol. 50(Suppl. 1): 134.
15. WESIERSKA-GADEK, J., A. GADEK, C. RANFTLER, et al. 2006. Anti-nuclear antibodies in sera from PBC patients specifically target p62 glycoprotein, a component of nuclear pore complexes. Autoimmunity Reviews (Abstracts of 5th Intern. Congress on Autoimmunity): 226-227.
16. STARR, C.M. & J.A. HANOVER. 1990. Glycosylation of nuclear pore protein p62. Reticulocyte lysate catalyzes O-linked N-acetylglucosamine addition in vitro. J. Biol. Chem. 265: 6868-6873.
17. CORDES, V., I. WAIZENEGGER & G. KROHNE. 1991. Nuclear pore complex glycoprotein p62 of Xenopus laevis and mouse: cDNA cloning and identification of its glycosylated region. Eur. J. Cell. Biol. 55: 31-47.
18. STARR, C.M., M. D'ONOFRIO, M.K. PARK, et al. 1990. Primary sequence and heterologous expression of nuclear pore glycoprotein p62. J. Cell. Biol. 110: 1861-1871.
19. BUSS, F., H. KENT, M. STEWART, et al. 1994. Role of different domains in the self-association of rat nucleoporin p62. J. Cell. Sci. 107(Pt 2): 631-638.
20. GREBER, U.F., A. SENIOR & L. GERACE. 1990. A major glycoprotein of the nuclear pore complex is a membrane-spanning polypeptide with a large lumenal domain and a small cytoplasmic tail. EMBO J. 9: 1495-1502.
21. WOZNIAK, R.W., E. BARTNIK & G. BLOBEL. 1989. Primary structure analysis of an integral membrane glycoprotein of the nuclear pore. J. Cell. Biol. 108: 2083-2092.
22. DICKSON, E.R., P.M. GRAMBSCH, T.R. FLEMING, et al. 1989. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 10: 1-7.
23. BANDIN, O., J.C. COURVALIN, R. POUPON, et al. 1996. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 23: 1020-1024.
24. INVERNIZZI, P., A. CROSIGNANI, P.M. BATTEZZATI, et al. 1997. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 25: 1090-1095.
25. NICKOWITZ, R.E. & H.J. WORMAN. 1993. Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein gp210. J. Exp. Med. 178: 2237-2242.
26. YANG, W.H., J.H. YU, A. NAKAJIMA, et al. 2004. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin. Gastroenterol. Hepatol. 2: 1116-1122.
27. MIYAKAWA, H., A. TANAKA, K. KIKUCHI, et al. 2001. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 34: 243-248.
28. MIYACHI, K., R.W. HANKINS, H. MATSUSHIMA, et al. 2003. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J. Autoimmun. 20: 247-254.
29. INVERNIZZI, P., M. PODDA, P.M. BATTEZZATI, et al. 2001. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J. Hepatol. 34: 366-372.
30. ITOH, S., T. ICHIDA, T. YOSHIDA, et al. 1998. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 13: 257-265.
31. MURATORI, P., L. MURATORI, R. FERRARI, et al. 2003. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am. J. Gastroenterol. 98: 431-437.
32. RIGOPOULOU, E.I., E.T. DAVIES, A. PARES, et al. 2005. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 54: 528-532.
33. ZUCHNER, D., T. STERNSDORF, C. SZOSTECKI, et al. 1997. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 26: 1123-1130.
34. INVERNIZZI, P., J. WESIERSKA-GADEK, P.M. BATTEZZATI, et al. 2004. Prognostic value of autoantibodies against proteins of nuclear pore complexes (anti-NPCs) in early primary biliary cirrhosis (PBC) [abstract]. J. Hepatol. 40: 159-160.
35. WESIERSKA-GADEK, J., E. PENNER, P.M. BATTEZZATI, et al. 2006. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 43: 1135-1144.
36. NAKAMURA, M., Y. SHIMIZU-YOSHIDA, Y. TAKII, et al. 2005. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J. Hepatol. 42: 386-392.
37. NAKAMURA, M., H. KONDO, T. MORI, et al. 2007. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45: 118-127.
38. JOSHI, S., K. CAUCH-DUDEK, E.J. HEATHCOTE, et al. 2002. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am. J. Gastroenterol. 97: 999-1002.